Cargando…
Brevilin A exerts anti-colorectal cancer effects and potently inhibits STAT3 signaling invitro
Colorectal cancer (CRC) is the third most common cause of cancer-related morbidity worldwide, with an estimated of 1.85 million new cases and 850,000 deaths every year. Nevertheless, the current treatment regimens for CRC have many disadvantages, including toxicities and off-targeted side effects. S...
Autores principales: | Meng, Mingjing, Tan, Jincheng, Chen, Hui, Shi, Zhiqiang, Kwan, Hiu-Yee, Su, Tao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10432182/ https://www.ncbi.nlm.nih.gov/pubmed/37593607 http://dx.doi.org/10.1016/j.heliyon.2023.e18488 |
Ejemplares similares
-
Brevilin A is a potent anti-metastatic CRC agent that targets the VEGF-IL6-STAT3 axis in the HSCs-CRC interplay
por: Fan, Xueying, et al.
Publicado: (2023) -
An Ethanolic Extract of Ampelopsis Radix Exerts Anti-colorectal Cancer Effects and Potently Inhibits STAT3 Signaling In Vitro
por: Su, Tao, et al.
Publicado: (2017) -
In vitro evaluation of anti-hepatoma activity of brevilin A: involvement of Stat3/Snail and Wnt/β-catenin pathways
por: Qin, Yaguang, et al.
Publicado: (2019) -
Baicalein is a novel TLR4‐targeting therapeutics agent that inhibits TLR4/HIF‐1α/VEGF signaling pathway in colorectal cancer
por: Chen, Minting, et al.
Publicado: (2021) -
Brevilin A, a Novel Natural Product, Inhibits Janus Kinase Activity and Blocks STAT3 Signaling in Cancer Cells
por: Chen, Xing, et al.
Publicado: (2013)